Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Third party research

OssDsign: Capital injection of SEK 158m - ABG

OssDsign

This is a third party research report and does not necessarily reflect our views or values

Download report (PDF)
Directed share issue and new financial targets
Sales > SEK 400m by '28e and EBIT/cash flow positive by ~'27e-'28e
Fund future growth, clinical trials and increased production


Directed share issue to fund future growth

OssDsign has carried out a directed share issue of 11.5m shares, corresponding to an increase of 11.8% in the number of shares in the company. Based on the closing price as of 3 June 2025, and before fees, this corresponds to an equity raise of approximately SEK 158m. The company states that the proceeds will be used to: 1) double the US sales force by '26e, 2) launch two new products during the ‘Strategy Period’ (2025–2028), 3) invest in clinical trials and expand the PROPEL spinal fusion registry, and 4) invest in production capacity to become more scalable and improve cost-efficiency, and 5) corporate purposes including quality assurance. If the issue is successful, the company believes it will be fully capitalised until it turns cash flow positive.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.